.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view requires addition of clients with MASLD and size of liver results in cardio-- kidney-- metabolic tests, when information advise mechanistically possible advantages and clinical security-- as well as details considerations for trial concept and regulative approval.